Integragen Stock

Integragen ROE

The Return on Equity (ROE) of Integragen (ALINT.PA) as of Aug 16, 2026 is 293.07 %. In the previous year, Return on Equity (ROE) was -14.59 % — a change of -2,109.13% (higher).

ROE

293.07 %

YoY

-2,109.13%

Last updated:

In 2026, Integragen's return on equity (ROE) was 293.07 %, a -2,109.13% increase from the -14.59 % ROE in the previous year.

Access this data via the Eulerpool API

Integragen Stock analysis

What does Integragen do? IntegraGen SA is a French biotechnology company based in Evry. It was founded in 2000 and is one of the leading companies in developing commercial applications in genomics and biology. The business model of IntegraGen SA consists of providing solutions and services for the diagnosis and treatment of various diseases, such as cancer, neurodegenerative diseases, and other genetically related diseases. The company is divided into two main areas: Diagnostics and Genomics. The Diagnostics area offers a wide range of services to its customers, including an oncology platform for the diagnosis and prediction of cancer using exclusive biomarker sets. Other diagnostic tests are used for the identification of microorganisms in clinical samples and the detection of autoimmune diseases. In the Genomics area, the focus is on the development and sale of PCR kits for genotyping single nucleotide polymorphisms (SNPs) and analysis kits for RNA expression. These solutions allow for the identification and validation of genes in specific biological samples in a way that improves customers' understanding and enables accurate findings. IntegraGen SA is committed to continuously developing new tests and platforms to help its customers achieve more precise diagnoses and better therapies. One notable development of the company is the screening kit "Arisk," which is specifically designed for identifying genotypes that have an increased risk of colorectal cancer. The screening kit uses specific SNPs to ensure that doctors can identify patients who require increased monitoring or even prophylactic surgery. The use of genomics technology and biomarker-based diagnostics is a growing trend in medicine. IntegraGen SA plays a significant role in enabling the integration of genomics into clinical practice, ensuring the best possible diagnosis and treatment for patients. In summary, IntegraGen SA is an innovative biotechnology company dedicated to providing solutions for the diagnosis and prevention of diseases using various technologies. The company is constantly striving to develop new products and services to provide customers and partners with the best possible diagnostic and therapeutic support. Integragen is one of the most popular companies on Eulerpool.

ROE Details

Decoding Integragen's Return on Equity (ROE)

Integragen's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Integragen's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Integragen's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Integragen’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Integragen stock

Return on Equity (ROE) of Integragen is 293.07 % in 2026.

Return on Equity (ROE) of Integragen changed from -14.59 % to 293.07 %, representing a -2,109.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Integragen since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Integragen with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Integragen

All Key Metrics — Integragen